Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Non-Diabetic Patients With HFpEF
NCT07112274Completed
- Sponsor
- Damanhour University
- Start
- Oct 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in heart failure with preserved ejection fraction (HFpEF) comparing Empagliflozin Group with Placebo Group (2 arms). Primary endpoints: N-Terminal Pro Brain Natriuretic Peptide at 3 months and soluble suppressor of tumorigenicity 2 at 3 months. Started Oct 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT07112274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07112274.